Honey composition with L-alanyl-L-glutamine
The present invention relates to compositions includes honey and L-alanyl-L-glutamine, pharmaceutical compositions thereof and a combined product comprising honey and L-alanyl-L-glutamine for a simultaneous, separate or sequential use in therapy. The composition, pharmaceutical composition and combined product have particular utility in improving sleep and treating sleep disorders such as insomnia or sleep apnoea.
1. A composition for improving sleep more efficiently than honey alone comprising honey in an effective amount to improve sleep in a subject in need thereof and 1% to 10% by weight of the composition of L-alanyl-L-glutamine or pharmaceutically acceptable salts thereof.
2. The composition of claim 1 , further comprising a solvent.
3. The composition of claim 1 , further comprising one or more pharmaceutically acceptable diluents, excipients, or carriers.
4. A combined product for improving sleep more efficiently than honey alone comprising honey in an effective amount to improve sleep in a subject in need thereof and 1% to 10% by weight of the composition of L-alanyl-L-glutamine or pharmaceutically acceptable salts thereof for simultaneous, separate, or sequential administration in sleep therapy.
5. The combined product of claim 4 , wherein the composition consists essentially of honey and L-alanyl-L-glutamine.
6. The composition of claim 1 , for use in the treatment of insomnia.
7. The composition of claim 1 , for use in treatment of sleep apnoea.
8. The combined product of claim 4 , for use in a method of improving sleep comprising the step of administering the combined product to the subject to be treated within 30 minutes prior to sleep.
9. The combined product of claim 6 , for use in a method of treating insomnia comprising the step of administering the composition to the subject to be treated within 30 minutes prior to sleep.
10. The composition of claim 7 , for use in a method of treating sleep apnoea comprising the step of administering the composition to the subject to be treated within 30 minutes prior to sleep.
11. The combined product of claim 4 , wherein the honey and L-alanyl-L-glutamine are prepared as a single composition.
12. A method for treating a sleep disorder by administering to a subject suffering from the sleep disorder the composition of claim 1 .
13. The method of claim 12 , wherein the sleep disorder is insomnia.
14. The method of claim 12 , wherein the sleep disorder is sleep apnoea.
15. The method of claim 12 , wherein the honey and L-alanyl-L-glutamine are administered as a composition consisting essentially of honey and L-alanyl-L-glutamine.
16. The method of claim 12 , wherein the honey and L-alanyl-L-glutamine are administered as a combined product comprising honey and L-alanyl-L-glutamine for simultaneous, separate, or sequential administration in sleep therapy.
17. The method of claim 16 , wherein the combined product consists essentially of honey and L-alanyl-L-glutamine.
18. The method of claim 12 , comprising the step of administering the honey and L-alanyl-L-glutamine to the subject to be treated within 30 minutes prior to sleep.
19. A method of improving sleep comprising administering to a subject in need of improved sleep the composition of claim 1 .
20. The method of claim 19 , wherein the honey and L-alanyl-L-glutamine are administered as a composition consisting essentially of honey and L-alanyl-L-glutamine.
21. The method of claim 19 , wherein the honey and L-alanyl-L-glutamine are administered as a combined product comprising honey and L-alanyl-L-glutamine for simultaneous, separate, or sequential administration in sleep therapy.
22. The method of claim 21 , wherein the composition consists essentially of honey and L-alanyl-L-glutamine.
23. The method of claim 19 , comprising the step of administering the composition to the subject to be treated within 30 minutes prior to sleep.
24. A composition for improving sleep more efficiently than honey alone comprising honey in a therapeutically effective amount to improve sleep in a subject in need thereof and 1% to 10% by weight of the composition of L-alanyl-L-glutamine or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable diluents, excipients, or carriers.